In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014)

Antimicrob Agents Chemother. 2016 Apr 22;60(5):3163-9. doi: 10.1128/AAC.03042-15. Print 2016 May.

Abstract

The activity of ceftazidime-avibactam was assessed against 961 isolates of meropenem-nonsusceptible Enterobacteriaceae Most meropenem-nonsusceptible metallo-β-lactamase (MBL)-negative isolates (97.7%) were susceptible to ceftazidime-avibactam. Isolates that carried KPC or OXA-48-like β-lactamases, both alone and in combination with extended-spectrum β-lactamases (ESBLs) and/or AmpC β-lactamases, were 98.7% and 98.5% susceptible to ceftazidime-avibactam, respectively. Meropenem-nonsusceptible, carbapenemase-negative isolates demonstrated 94.7% susceptibility to ceftazidime-avibactam. Ceftazidime-avibactam activity was compromised only in isolates for which carbapenem resistance was mediated through metallo-β-lactamases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Azabicyclo Compounds / pharmacology*
  • Carbapenems / pharmacology*
  • Ceftazidime / pharmacology*
  • Enterobacteriaceae / drug effects*
  • Enterobacteriaceae / enzymology
  • Microbial Sensitivity Tests
  • beta-Lactamases / genetics
  • beta-Lactamases / metabolism

Substances

  • Azabicyclo Compounds
  • Carbapenems
  • avibactam
  • Ceftazidime
  • beta-Lactamases

Grants and funding

This investigation was funded by AstraZeneca Pharmaceuticals as part of the sponsored INFORM global surveillance program. The sponsor approved the overall study design. All investigative sites were recruited and study supplies were provided by IHMA, Inc. Analysis of the final MIC and molecular data was performed by IHMA.